Dossier assessment
Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with moderately to severely active ulcerative colitis
- Patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or were intolerant to a biologic agent (TNFα antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
Press releases
Ulcerative colitis: Comparative study provides important insights
Additional information
Federal Joint Committee (G-BA)
2025-11-20 A G-BA decision was published.
Project details
- Project no.
- A25-74
- Commission
- Commission awarded on 03.06.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-74_en
Connected Projects
-
Dossier assessment
Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Guselkumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Guselkumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed